TG THERAPEUTICS, INC. (TGTX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001001316 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 3, 2026 | $240.3M | $7.8M | $0.05 | Filing |
| Mar 31, 2026 | May 6, 2026 | $204.9M | $19.8M | $0.12 | Filing |
| Dec 31, 2025 | Feb 26, 2026 | $192.6M | $23.1M | $0.14 | Filing |
| Sep 30, 2025 | Nov 3, 2025 | $161.7M | $390.9M | $2.43 | Filing |
| Jun 30, 2025 | Aug 4, 2025 | $141.1M | $28.2M | $0.17 | Filing |
| Mar 31, 2025 | May 5, 2025 | $120.9M | $5.1M | $0.03 | Filing |
| Dec 31, 2024 | Mar 3, 2025 | $108.2M | $23.3M | $0.16 | Filing |
| Sep 30, 2024 | Nov 4, 2024 | $83.9M | $3.9M | $0.02 | Filing |
What would TG THERAPEUTICS, INC. have to report for its valuation to change?
At $53.97, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 11.0% a year, to $4.61. On that path the next quarter needs diluted EPS near $2.70, against $2.43 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 11.0% | 11.0% |
| EPS needed in final year | $4.61 | $4.61 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. TGTX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.